NanoViricides Inc. Stock
€1.28
Your prediction
NanoViricides Inc. Stock
Pros and Cons of NanoViricides Inc. in the next few years
Pros
Cons
Performance of NanoViricides Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| NanoViricides Inc. | -3.760% | 3.101% | -16.352% | 5.556% | 40.741% | -65.220% | 725.062% |
| Actinium Pharmaceuticals Inc. | 1.450% | 5.368% | -0.118% | -69.028% | -62.655% | -77.189% | -73.509% |
| Immunic Inc. | -1.100% | 7.301% | 15.111% | 14.028% | 1.748% | -78.460% | -84.684% |
| AnaptysBio Inc | 0.640% | 9.028% | -3.681% | 84.706% | 61.856% | 33.051% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of NanoViricides Inc. (NNVCE), a company situated in the biotechnology and medical research arena, the overall impression reveals a combination of potential and pitfalls. Given its market capitalization hovering around $21.9 million, the financial landscape illustrates challenges that need strategic management. With no reported revenue and negative earnings, the path to profitability appears steep. However, it is essential to scrutinize deeper into both the pros and cons to gain a clearer perspective on NanoViricides' current standing and future prospects.
Low Price to Book Ratio: The current price to book ratio of 1.1771 indicates that the market valuing the company is relatively modest when compared to its book value. This could suggest that the stock is undervalued and may attract potential investors who see an opportunity for growth and recovery.
Enterprise Value Comparison: The enterprise value of approximately $20.8 million compared to the negative EBITDA (earning before interest, taxes, depreciation, and amortization) of -$9.04 million indicates that while the company is currently not generating profits, the market sentiment remains somewhat stable. The negative EBITDA might raise red flags, but it also signifies that the company may have room for improvement if operational strategies are successfully revamped.